EP
LXEO icon

Essential Partners’s Lexeo Therapeutics LXEO Stock Holding History

Essential Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Sell
354
-117
-25% -$633 ﹤0.01% 2053
2026
Q1 		$2.7K Sell
471
-5
-1% -$35 ﹤0.01% 1878
2025
Q4 		$4.73K Buy
476
+5
+1% +$46 ﹤0.01% 1454
2025
Q3 		$3.13K Buy
471
+297
+171% +$1.44K ﹤0.01% 1620
2025
Q2 		$699 Buy
+174
New +$572 ﹤0.01% 1603

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Essential Partners's LXEO Position: Q2 2026 in Review

Essential Partners reduced its Lexeo Therapeutics (LXEO) stake by 25% in Q2 2026, selling an estimated $633 and leaving 354 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2053.

Essential Partners first reported a position in LXEO in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.73K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Essential Partners held 354 shares of Lexeo Therapeutics worth $1.65K as of Q2 2026.
  • Essential Partners sold 117 Lexeo Therapeutics shares in Q2 2026, an estimated $633.
  • Lexeo Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2053 holding.
  • Essential Partners first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Lexeo Therapeutics position peaked at $4.73K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.